Early low-dose deferasirox to prevent iron overload in lower-risk MDS

Phase 2, open-label, single-arm trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Fondazione Italiana Sindromi Mielodisplastiche. Primary endpoint: Primary: Change of hepatic iron from baseline according to baseline hepatic iron level. Started May 2021; status: terminated.